MedTech Acquisition Corporation (MTAC) Adjourns Completion Vote
by Marlena Haddad on 2023-08-02 at 5:26pm

MedTech Acquisition Corporation (Nasdaq: MTAC) announced this afternoon that it convened and then adjourned its completion vote for its business combination with drug developer TriSalus Life Sciences.

The special meeting, initially planned for today, has been rescheduled to 11:00 a.m. ET on August 8. In connection with the adjournment, MedTech has extended the deadline for stockholders to submit their shares for redemption to 5:00 p.m. ET on August 4.

Prior to today’s meeting, MTAC filed an 8-K regarding the written response received by TriSalus from the FDA in reference to a meeting request for TriSalus’ PERIO-01 clinical program. The FDA acknowledged that early data from the program showed that TriSalus’ pressure-enabled drug delivery (PEDD) method had a tolerable safety profile and has requested further exploration of the dose before proceeding with a registrational trial.

TriSalus plans to have Phase 1 efficacy data for multiple SD-101 doses by the second half of 2023. As a result of the FDA’s responses, TriSalus expects a potential new drug application submission for SD-101 in uveal melanoma with liver metastases to likely occur beyond 2025, pending Phase 2 data.

MedTech initially announced its $234 million combination with TriSalus Life Sciences in November. Within the past few months, the parties agreed to drop the deal’s minimum cash condition to $35 million from $60 million. Additionally, the SPAC disclosed last month that it added a $17.8 million convertible share investment and a $2 million backstop to its combination with the drug developer.

Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device. In April, TriSalus presented clinical data from its Phase I trials, which indicated positive results in reducing tumor growth in liver cancer patients.

The combined company is expected to trade on the Nasdaq under the symbol “TLSI” once the deal is completed.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-07-19 at 12:46pm

Vine Hill Capital Investment Corp. (NASDAQ:ESPAU) has filed for a $200 million IPO, which marks underwriter Stifel Nicolaus’ return to the SPAC market after a hiatus of over two years. Stifel last served as a book-runner for a SPAC when filing for Kensington Capital IV in January 2022 and hasn’t acted as left-lead since Spree...

by Nicholas Alan Clayton on 2024-07-19 at 8:13am

At the SPAC of Dawn SPACs may be back on the upswing, but it seems increasingly unlikely they will return to the same stomping grounds as in 2020-2022. Teams took 14 Fintech firms public during those years, 17 more in broader Financial Services and five more in Crypto. But, those sectors may no longer hold...

by Nicholas Alan Clayton on 2024-07-18 at 1:18pm

Expectation Acquisition Corporation (NASDAQ:ESPAU) has filed to bring another Oppenheimer alum back to the market with a $60 million SPAC IPO. That officer is Expectation CFO Chi Zhuang, who started out as an equity research associate at the firm’s New York office in 2014. This overlapped with a period when Lewis Silberman, co-CEO of yesterday’s...

by Kristi Marvin on 2024-07-18 at 10:19am

In the past few months we’ve seen a number of SPACs IPO using what we like to call “anchor investors”, a term we use as a bit of shorthand.  What that means is, the bankers round out the IPO with qualified institutional buyers, sometimes called “non-managing sponsor investors”, that indicate for up to 9.9% of...

by Nicholas Alan Clayton on 2024-07-18 at 8:20am

At the SPAC of Dawn Stardust Power (NASDAQ:SDST) is the latest de-SPAC to rocket up this week after closing its combination with Global Partner II, but there could be more to its spike than simply the low float it currently represents. The parties got through their July 8 closing with just 134,550 public shares remaining...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved